Gout Learning Center

About Gout

Gout is a common and chronic disease, affecting more than 8 million individuals in the United States; its prevalence has increased in recent decades and will continue to increase as the population ages. Ambulatory visits for gout in the United States increased nearly 3-fold from 1993 to 2009, with most of the increase taking place from 2003 on. It is now known that hyperuricemia can not only precipitate gout but also lead to a host of serious health consequences if left undiagnosed, untreated, or undertreated.

Suboptimal management puts gout patients at risk for permanent joint damage and a wide range of potentially life-threatening cardiovascular, renal, metabolic, and other comorbid diseases. Patients may believe that gout can be managed by treating acute episodes as they occur, but evidence clearly shows that patients for whom urate-lowering therapy is indicated need to be managed long-term with medication, monitoring, and dose adjustments as needed.

Additional Gout CME/CE

Updated Guidelines for Gout Treatment: Pearls for Practice

In this educational activity, 2 gout clinical experts review key pearls from evidence-based guidelines for gout management, including those from the ACP, ACR, and EULAR. Key differences among the recommendations relative to the long-term management of hyperuricemia will be discussed in detail, and the implications for clinical practice will be reviewed.
CME/CE 0.50
Engaging the Patient with Gout in Long-Term Treatment

In this educational activity, 2 gout experts review strategies for educating patients with gout about the potential consequences of hyperuricemia and provide guidance on both pharmacologic and nonpharmacologic approaches to treatment. The importance of keeping patients with gout engaged in treatment over the long term is discussed.
CME/CE 0.50
Identifying and Addressing Persistent Hyperuricemia in Gout

This educational activity features an in-depth discussion of the potential effects of uncontrolled hyperuricemia. Available and emerging urate-lowering therapy is discussed in detail. The faculty also reviews the importance of educating patients with gout about the potential effects of hyperuricemia and the importance of long-term adherence.
CME/CE 0.50

Faculty

Paul Doghramji, MD
Family Physician
Collegeville Family Practice
Collegeville, PA

Michael Pillinger, MD
Professor of Medicine and Biochemistry and Molecular Pharmacology
Director, Crystal Disease Study Group
Director, Masters of Science in Clinical Investigation
Director, Rheumatology Training
New York University School of Medicine
New York, NY

Naomi Schlesinger, MD
Professor of Medicine
Chief, Division of Rheumatology
Department of Medicine
Rutgers - Robert Wood Johnson Medical School
New Brunswick, NJ

Robert Terkeltaub, MD
Professor of Medicine
Division of Rheumatology and Immunology
University of California San Diego
San Diego, CA

Arthur Weaver, MD, MS, FACP, MACR
Clinical Professor of Medicine Emeritus
Department of Medicine, Section of Rheumatology
University of Nebraska Medical Center
Omaha, NE

Accreditation

Jointly provided by

In collaboration with

Supported by
an educational grant from

Ironwood Pharmaceuticals, Inc.